1. Home
  2. TIPT vs ANL Comparison

TIPT vs ANL Comparison

Compare TIPT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiptree Inc.

TIPT

Tiptree Inc.

HOLD

Current Price

$17.76

Market Cap

663.9M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.00

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIPT
ANL
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
663.9M
731.6M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
TIPT
ANL
Price
$17.76
$10.00
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$20.00
AVG Volume (30 Days)
249.3K
109.5K
Earning Date
05-12-2026
04-10-2026
Dividend Yield
1.40%
N/A
EPS Growth
N/A
N/A
EPS
0.34
N/A
Revenue
$488,000.00
N/A
Revenue This Year
N/A
$36.02
Revenue Next Year
N/A
N/A
P/E Ratio
$50.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.49
$0.88
52 Week High
$27.38
$17.25

Technical Indicators

Market Signals
Indicator
TIPT
ANL
Relative Strength Index (RSI) 50.84 38.72
Support Level $17.19 $6.92
Resistance Level $17.56 $9.98
Average True Range (ATR) 0.40 1.15
MACD -0.05 -0.00
Stochastic Oscillator 19.21 1.82

Price Performance

Historical Comparison
TIPT
ANL

About TIPT Tiptree Inc.

Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: